Ligand Pharmaceuticals Inc. (LGND) financials — revenue, cash, debt and margins

Ligand Pharmaceuticals Inc. (LGND) financials — revenue, cash, debt and margins — InspectStocks

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $6.2B
P/E (TTM): 32.98
Price / sales: 21.30
EV / EBITDA: 46.70
Price / book: 6.40

Cash flow

FCF yield: 2.1%
SBC-adjusted FCF yield: 1.3%
SBC impact: 40.5%
Stock compensation (TTM): $53.3M

Margins & growth

Profit margin: 67.9%
Operating margin: 32.6%
Quarterly revenue (year on year): 33.7%
Quarterly earnings (year on year): 900.8%

Balance sheet

Cash & investments: $1.4B
Debt: $1.1B
Net cash / (debt): $226.3M

Where the revenue comes from

Income From Divestiture Transactions is 20% of revenue.

By product or service

Year to Dec 31, 2025 · $268.1M

Income From Divestiture Transactions20%
$53.1M
Material Sales Captisol Core15%
$40.2M+30.2% vs. a year earlier
Royalty Kyprolis13%
$35.5M-7.4% vs. a year earlier
Filspari12%
$32M+162.5% vs. a year earlier
QARZIBA9%
$23.7M+113.5% vs. a year earlier
Royalty Rylaze5%
$13.4M-2.9% vs. a year earlier
Royalty Other4%
$10.4M+38.5% vs. a year earlier
Capvaxive4%
$10.1M+1,506.9% vs. a year earlier
Ohtuvayre4%
$9.8M+1,071.7% vs. a year earlier
Royalty Teriparatide Injection3%
$8.1M-0.9% vs. a year earlier
Vaxneuvance3%
$7.4M+42.8% vs. a year earlier
License Fees3%
$7M+259.5% vs. a year earlier
Service3%
$6.8M-73.3% vs. a year earlier
Royalty Evomela2%
$5.9M-31.5% vs. a year earlier
Financial Royalty Other2%
$4.7M+103.4% vs. a year earlier

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$290.54MQ2 2026+5.9%

1Y: +54.89%2Y: +117.67%5Y: +22.44%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

EBITDA

$127.65MQ2 2026-0.1%

1Y: +19,629.06%2Y: +580.68%5Y: +6.31%

Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

$197.22MQ2 2026+28.4%67.9% of revenue

1Y: +359.97%2Y: +367.98%5Y: +311.80%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

67.9%Q2 2026+21.3%

How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.

Free Cash Flow

$131.44MQ2 2026+6.8%

1Y: +145.13%2Y: +183.63%5Y: +265.59%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

$9.41Q2 2026+26.6%

1Y: +332.92%2Y: +307.36%5Y: +239.71%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.

Shares outstanding

20.75MQ2 2026+2.4%

How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.

Price to earnings

39.8xQ2 2026+21.8%

39.8x today · median 40.8x and range 2.4x–93.1x across the points shown, Q1 2019 to Q2 2026 The breaks in the line cover 10 periods with no meaningful multiple — a loss, or earnings so small the ratio says more about the denominator than the price.

Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.

About Ligand Pharmaceuticals Inc.

Ticker: LGND
SEC classification: Pharmaceutical Preparations (2834)
Listed on: Nasdaq, OTC
Incorporated in: DE
Financial year ends: December 31
Filer size: Large accelerated filer

About this data

Everything above comes from Ligand Pharmaceuticals Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Gross Profit, Total Operating Expenses, Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Borrowings, Borrowings (total), and Dividends paid. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.